Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $152 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a $152 price target.
June 01, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Ascendis Pharma and maintained a $152 price target.
The reiteration of an Overweight rating and maintenance of a $152 price target by Cantor Fitzgerald analyst Li Watsek indicates a positive outlook for Ascendis Pharma. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100